Ospemifene for vulvar and vaginal atrophy: an overview

Santiago Palacios MD, PhD

Article Type

Editorial

Published

This editorial article introduces a Special Focus Issue entitled “Treatment of Vulvar and Vaginal Atrophy: Clinical Experience with Ospemifene”. Ospemifene is a selective estrogen receptor modulator indicated for treatment of moderate-to-severe symptomatic vulvar and vaginal atrophy in postmenopausal women who are not candidates for local vaginal estrogen therapy or have contraindications for estrogen products.

Read more

Clinical study of the tolerability of calcium carbonate–casein microcapsules as a dietary supplement in a group of postmenopausal women

Santiago Palacios PhD, MD, Marieta Ramirez MD, Mariella Lilue MD

Article Type

Original Research

Published

This article reviews the tolerability of a new delivery system for calcium supplementation, based on the functionalization of calcium carbonate (CaCO3) particles by casein proteins, in a randomized, prospective, double-blind, active comparator clinical trial.

Read more

Management of psoriasis in pregnancy – a review of the evidence to date

Clara Ferreira MD, Alexandra Azevedo MD, Miguel Nogueira MD, Tiago Torres MD, PhD

Article Type

Review

Published

This article reviews the impact of psoriasis during pregnancy, how the disease can be managed pharmacologically during this period according to the available armamentarium, and the possible effects of the therapeutic options for the mother and the foetus.

Read more

Hemorrhoid management in women: the role of tribenoside + lidocaine

Jan Kestřánek MD

Article Type

Review

Published

This paper reviews various options in current therapy for hemorrhoids in women—namely, medical intervention (topical and systemic drug therapy)—and discusses the available clinical evidence for an appropriate use of over-the-counter topical formulations for the symptomatic treatment of hemorrhoids.

Read more

Palbociclib in metastatic breast cancer: current evidence and real-life data

Francesco Serra MD, Pietro Lapidari MD, Erica Quaquarini MD, Barbara Tagliaferri MD, Federico Sottotetti MD, Raffaella Palumbo MD, PhD

Article Type

Review

Published

This review summarizes the background and latest evidence for the use of palbociclib, an oral, first-in-class, highly selective cyclin-dependent kinase 4/6 inhibitor, in advanced breast cancer, with a focus on some of the unanswered questions about the performance of this agent in clinical practice.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.